Clinical Trial

A Phase I/II Study of Diffuse Large B-cell Lymphoma

Study acronym: DLBL
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 23, 2021 (before its estimated December 31, 2023 completion). Its status may not reflect the trial's current state.
Summary
For continuous variables, mean, median, minimum, and maximum will be used for the descriptive purpose. For categorical variables, frequency and percentage will be used for descriptive statistics. The variables of OS will be estimated by the Kaplan-Meier method. Differences between groups will be calculated using the log-rank test for univariate analysis. Cox's proportional hazards model will be employed to test independent prognostic factors. All calculations will be performed using the Statistical Package of Social Sciences software, version 17.0 (SPSS, Inc., Chicago, IL, USA). The level of statistical significance will be set at 0.05 for all tests.
Trial Details
NCT Number NCT04856137
Lead Sponsor National Health Research Institutes, Taiwan
Collaborators: Taipei Veterans General Hospital, Taiwan, Chang Gung Memorial Hospital, China Medical University Hospital, Shin Kong Wu Huo-Shih Memorial Hospital
Conditions Refractory Diffuse Large B-cell Lymphoma
Enrollment 74 participants
Start Date 2021-05-01
Primary Completion 2023-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2021-04-23